Agendia Touts ASCO Guideline's Endorsement Of MammaPrint Breast Cancer Test
Executive Summary
Results of the MINDACT trial, which show that Agendia BV's MammaPrint 70-gene lab test can identify about half of the early-stage breast cancer patients who do not need chemotherapy, has led the American Society of Clinical Oncology to specifically recommend the test in its guidelines.